News and commentary from the endocrinology world
Limited benefit seen in patients with established cirrhosis, however
More noteworthy research from the EASD 2024 meeting
Saxenda group six times more likely to lose at least 5% of BMI
Approximately one-fourth of new users in 2023 did not have type 2 diabetes